000 01104cam a22003014a 4500
005 20250914145250.0
008 050503s2005 flua b 001 0 eng
020 _a157444882X (alk. paper)
_cRM711.70
039 9 _a200606191301
_bzainol
_c200606080845
_drazalis
_y06-08-2006
_zrazalis
060 _aQV 771
_b. P9227 2005
090 _aQV771.P922 2005
245 0 0 _aPreclinical drug development /
_c[edited by] Mark C. Rogge, David R. Taft
260 _aBoca Raton :
_bTaylor & Francis,
_c2005
300 _axiv, 575 p. :
_bill. ;
_c23 cm.
440 0 _aDrugs and the pharmaceutical sciences ;
_vv. 152
650 2 _aDrug Evaluation, Preclinical
_xmethods
650 2 _aDrug Industry
_xmethods
700 1 _aRogge, Mark C.
700 1 _aTaft, David R.
856 4 2 _3Publisher description
_uhttp://www.loc.gov/catdir/enhancements/fy0648/2005048422-d.html
907 _a.b13744112
_b2019-11-12
_c2019-11-12
942 _c01
_n0
_kQV771.P922 2005
914 _avtls003328776
990 _azr
991 _aJabatan Farmasi
998 _ad
_b2006-08-06
_cm
_da
_feng
_gflu
_y0
_z.b13744112
999 _c372766
_d372766